Chemify secures $50M Series B to expand digital chemistry lab

Chemify has closed an oversubscribed Series B round of just over $50 million, securing capital to roll out its digital chemistry stack and automated labs beyond the UK. The financing was led by top-tier growth investors, and brings fresh firepower to the company’s effort to turn chemical synthesis into a programmable, data-driven process.

The oversubscribed round was co-led by Wing Venture Capital and Insight Partners, with participation from a syndicate of world-class investors including 8VC and existing backers Triatomic Capital, Blueyard, Rockspring and Eos.

The funding will be channelled into expanding the company’s hybrid offering: the Chemputation software layer — a purpose-built AI and programming architecture for chemistry — and the physical, automated pilot sites known as Chemifarm facilities. Chemify says the combined hardware-software approach lets researchers design, validate and manufacture small molecules with far shorter turnaround than traditional workflows.

Founded as a spin-out from the University of Glasgow in 2022, Chemify built its first automated site in Glasgow. With this injection of capital the company will establish a West Coast technical hub in Silicon Valley led by Chief Technical Officer Mike Bell, alongside additional international Chemifarms. Founder and CEO Lee Cronin frames the strategy as a push to make complex molecules ‘makeable’ at scale, serving partners across drug discovery, advanced materials and industrial chemistry.

Looking ahead, Chemify will use the Series B to scale capacity, add reaction data to its library, and deepen pharmaceutical partnerships. The capital also funds further productisation of Chemputation so industrial teams can integrate the platform into internal labs. If successful, Chemify aims to set a new standard for how small molecules are designed, tested and produced worldwide.